Skip to main content
. 2023 Dec 1;38(6):1149–1154. doi: 10.1038/s41433-023-02849-6

Fig. 2. Flowchart showing the dosing regimen for subjects enrolled in the study.

Fig. 2

Cohort 1 subjects were pretreated with aflibercept, cohort 2 subjects with bevacizumab and ranibizumab, and cohort 3 subjects with aflibercept, ranibizumab and bevacizumab.